Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Pierre Baumann, Philipp Bauknecht, Maxim Kuzin & Georgios Schoretsanitis. (2023) Switching antipsychotics to partial dopamine D2-agonists in individuals affected by schizophrenia: a narrative review. International Journal of Psychiatry in Clinical Practice 27:4, pages 367-384.
Read now
Read now
David Fraguas, David Almenta Gallego, Sergio Arques-Egea, Marcos Gómez-Revuelta, Carlos Gómez Sánchez-Lafuente, Daniel Hernández Huerta, Daniel Núñez Arias, Beatriz Oda Plasencia-García, Carlos Parro Torres, Samuel Leopoldo Romero-Guillena, Elena Ros Cucurul & Cecilio Alamo. (2023) Aripiprazole for the treatment of schizophrenia: Recommendations of a panel of Spanish experts on its use in clinical practice. International Journal of Psychiatry in Clinical Practice 27:1, pages 82-91.
Read now
Read now
Juan Carlos García Álvarez, Luz González Sánchez, Eloy García Resa, José María Bonete Llácer, Ana Román Rodríguez, Beatriz Pecino Esquerdo & Enrique Pérez Martínez. (2020) Clinical evolution of patients treated with aripiprazole long-acting injectable: a preliminary, prospective, observational study. International Journal of Psychiatry in Clinical Practice 24:1, pages 10-17.
Read now
Read now
Martha Sajatovic, Faith DiBiasi & Susan N Legacy. (2017) Attitudes toward antipsychotic treatment among patients with bipolar disorders and their clinicians: a systematic review. Neuropsychiatric Disease and Treatment 13, pages 2285-2296.
Read now
Read now
Andrea Fagiolini, Emilia Alfonsi, Giovanni Amodeo, Mario Cenci, Michele Di Lella, Francesco Farinella, Fabrizio Ferraiuolo, David Fraguas, Natale Loparco, Luis Gutierrez-Rojas, Maria Laura Mignone, Giuseppe Pataracchia, Gianluca Pillai, Felicia Russo, Vanessa Sanchez-Gistau, Franco Spinogatti, Marco Toscano, Vincenzo Villari & Sergio De Filippis. (2016) Switching long acting antipsychotic medications to aripiprazole long acting once-a-month: expert consensus by a panel of Italian and Spanish psychiatrists. Expert Opinion on Drug Safety 15:4, pages 449-455.
Read now
Read now
Guido Di Sciascio & Marco Andrea Riva. (2015) Aripiprazole: from pharmacological profile to clinical use. Neuropsychiatric Disease and Treatment 11, pages 2635-2647.
Read now
Read now
Articles from other publishers (10)
Elmars Rancans, Zsófia Borbála Dombi & Ágota Barabássy. (2022) Dosing Cariprazine Within and Beyond Clinical Trials: Recommendations for the Treatment of Schizophrenia. Frontiers in Psychiatry 12.
Crossref
Crossref
Chia-Hao Ma, Hung-Yu Chan, Ming H. Hsieh, Chen-Chung Liu, Chih-Min Liu, Hai-Gwo Hwu, Ching-Hua Kuo, Wei J. Chen & Tzung-Jeng Hwang. (2022) Identifying dopamine supersensitivity through a randomized controlled study of switching to aripiprazole from other antipsychotic agents in patients with schizophrenia. Therapeutic Advances in Psychopharmacology 12, pages 204512532110643.
Crossref
Crossref
Li Qian, Liao Xuemei, Li Jitao, Su Yun'Ai & Si Tianmei. (2021) Dose-Dependent Efficacy of Aripiprazole in Treating Patients With Schizophrenia or Schizoaffective Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in Psychiatry 12.
Crossref
Crossref
Hiroshi Kimura, Nobuhisa Kanahara & Masaomi Iyo. (2021) Rationale and neurobiological effects of treatment with antipsychotics in patients with chronic schizophrenia considering dopamine supersensitivity. Behavioural Brain Research 403, pages 113126.
Crossref
Crossref
Michael M. C. Wong, Albert K. K. Chung, Timothy M. H. Yeung, David T. W. Wong, C. K. Lee, Eric Lai, Gloria F. Y. Chan, Gregory K. L. Mak, Jessica O. Y. Wong, Roger M. K. Ng, K. L. Tam & K. Y. Mak. (2020) Consensus statements on the clinical usage and characteristics of aripiprazole for Hong Kong. Internal Medicine Journal 50:S3, pages 6-14.
Crossref
Crossref
Jun Ishigooka, Tomohiro Usami, Shuichi Iwashita, Yoshitsugu Kojima & Satoshi Matsuo. (2020) Post‐hoc analysis investigating the safety and efficacy of brexpiprazole in Japanese patients with schizophrenia who were switched from other antipsychotics in a long‐term study (Secondary Publication). Neuropsychopharmacology Reports 40:2, pages 122-129.
Crossref
Crossref
Jiří Masopust. (2020) Aripiprazole in the form of long-acting intramuscular injections in the clinical practice. Psychiatrie pro praxi 21:1, pages 40-46.
Crossref
Crossref
Baybars Veznedaroglu, Nesrin Dilbaz, Ozcan Uzun & Erdal Isik. (2018) TARC: Turkish aripiprazole consensus report- Aripiprazole use and switching from other antipsychotics to aripiprazole- consensus recommendations by a Turkish multidisciplinary panel. Therapeutic Advances in Psychopharmacology 8:10, pages 271-285.
Crossref
Crossref
Enrico Biagi, Enrico Capuzzi, Fabrizia Colmegna, Alessandra Mascarini, Giulia Brambilla, Alessandra Ornaghi, Jacopo Santambrogio & Massimo Clerici. (2017) Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly. Advances in Therapy 34:5, pages 1036-1048.
Crossref
Crossref
P. Sánchez Páez, J.L. Gómez Cano, L. Sánchez Flores, R. González Lucas & P. Artieda Urrutia. (2020) Aripiprazole once monthly outpatient experience. European Psychiatry 41:S1, pages S760-S760.
Crossref
Crossref